Efficacy and Tolerance of Treatment With DHA, Choline and Vitamin E in Children With Non-alcoholic Steatohepatitis

Last updated: January 13, 2016
Sponsor: Bambino Gesù Hospital and Research Institute
Overall Status: Completed

Phase

3

Condition

Metabolic Syndrome

High Cholesterol (Hyperlipidemia)

Scar Tissue

Treatment

N/A

Clinical Study ID

NCT01934777
OPBG-DHA, VIT E, CHOLINE
  • Ages 4-16
  • All Genders

Study Summary

The purpose of this interventional study is to evaluate the efficacy and tolerability of docosahexaenoic acid (DHA), Vitamin E and Choline in children or adolescents with well-characterized and liver biopsy confirmed nonalcoholic fatty liver disease (NAFLD).

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • persistently elevated serum aminotransferase levels

  • diffusely echogenic liver on imaging studies suggestive of fatty liver

  • biopsy consistent with the diagnosis of NAFLD

Exclusion

Exclusion Criteria:

  • hepatic virus infections (HCV RNA-PCR negative)

  • Hepatitis A, B, C, D, E and G

  • cytomegalovirus and Epstein-Barr virus

  • alcohol consumption

  • history of parenteral nutrition

  • use of drugs known to induce steatosis or to affect body weight and carbohydratemetabolism

  • autoimmune liver disease, metabolic liver disease, Wilson's disease, anda-1-antitrypsin-associated liver disease were ruled out using standard clinical,laboratory and histological criteria

Study Design

Total Participants: 60
Study Start date:
October 01, 2013
Estimated Completion Date:
July 31, 2015

Study Description

Sixty children or adolescents (4-16 years) with liver biopsy proven NAFLD will be enrolled. They will be randomized to treatment with DHA, VIT E and Choline (n=30)or an identical placebo (n=30) given orally for a period of 12 months. All patients will be included in a lifestyle intervention program consisting of a diet tailored on the individual requirements and physical exercise.

Patients will undergo a medical evaluation every three months during the 12-month study period. Liver biopsy will be performed at baseline and at 12 months. Anthropometric analysis, laboratory tests, including liver enzymes and lipids will be repeated at 3-month intervals during the 12-months study duration. Ultrasonography of the liver will be repeated after six months at the end of the study period.

Connect with a study center

  • Bambino Gesù Hospital and Research Institute

    Rome, Rome, Italy 00165
    Italy

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.